Unfortunately, treatment for stroke has traditionally been very restricted as the only therapeutic option proven to result in improved clinical outcomes is tissue plasminogen activator (tPA), which has notable limitations in its application due to its exceptionally short therapeutic administration window of 4.5 h after symptom onset [7,8]. The gene discussed is PLAT; the disease is stroke disorder.